Mylan Inc. and Watson Pharmaceuticals Inc. have received approval from the Food and Drug Administration for sildenafil citrate tablets (20 mg), a hypertension medication.


Mylan, Watson, Revatio generics, sildenafil citrate tablets, generic version of Revatio, Pfizer, Food and Drug Administration, pulmonary arterial hypertension






































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks

Mylan, Watson cleared to market Revatio generics

November 13th, 2012

NEW YORK – Mylan Inc. and Watson Pharmaceuticals Inc. have received approval from the Food and Drug Administration for sildenafil citrate tablets (20 mg), a hypertension medication.

Both companies' products are generic versions of Pfizer's Revatio, which is used to treat pulmonary arterial hypertension and improve exercise ability in men and women, as well as delay clinical worsening.

Mylan said Tuesday that it has begun shipping its Revatio generic. Watson, which announced its generic version of Revatio Monday, said it expects to release its product soon.

For the 12 months ended Sept. 30, Revatio tablets had total U.S. sales of about $339 million, according to IMS Health figures cited by Mylan and Watson.

More Supplier News Breaks >>
Advertisement